Alpha memo: metformin resistance training

One-sentence alpha: Metformin may blunt specific molecular and structural adaptations to resistance training in older adults while leaving aerobic-exercise-related glycaemic gains largely preserved in metformin-treated type 2 diabetes patients. Receipt 1: Metformin alters skeletal muscle transcriptome adaptations to resistance training in older adults (Aging, 2020) — In a 14-week PRT trial, metformin blunted PRT-induced muscle hypertrophy and attenuated the number of differentially expressed genes within PRT-responsive extracellular matrix remodeling and RNA processing pathways compared with placebo. Receipt 2: Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both? (Diabetologia, 2013) — In the DARE trial of adults with type 2 diabetes, aerobic training produced a significant HbA1c reduction in metformin users versus control, and metformin use did not abolish the aerobic-exercise glycaemic benefit, although resistance-only and combined effects were more modest in metformin users. Why this is surprising: Receipt 1 establishes that metformin can interfere with resistance-training biology at the transcriptomic and hypertrophic level, yet Receipt 2 suggests the downstream glycaemic response to aerobic training survives metformin exposure — the same drug–exercise interaction thus appears molecularly disruptive but metabolically bounded. Caveats/falsifiers:

• Receipt 1 is in non-diabetic older adults at one PRT dose over 14 weeks; Receipt 2 is in adults with type 2 diabetes on metformin across aerobic, resistance, and combined modalities over 22 weeks — the populations, modalities, and endpoints differ, so the signals are only analogous, not equivalent.
• A decisive future falsifier would be a randomized trial in type 2 diabetes showing that metformin abolishes aerobic-exercise-induced HbA1c reductions by a clinically meaningful margin (>0.3%) and blunts muscle hypertrophy on resistance training.